Monday’s Midday Stock Update: ACADIA Pharmaceuticals Inc (ACAD), Exact Sciences (EXAS), Arrowhead Research (ARWR), Rite Aid Corp (RAD), Veeva Systems (VEEV)

By Carrie Williams

So far Monday, September 9, NASDAQ is down -1.54% and the S&P is down -1.26%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; ACADIA Pharmaceuticals Inc (ACADResearch Report), Exact Sciences (EXASResearch Report), Arrowhead Research (ARWRResearch Report), Rite Aid Corp (RADResearch Report) and Veeva Systems (VEEVResearch Report).

ACADIA Pharmaceuticals Inc is down -9.39% in midday trading to $37.83. Shares opened today at $41.75. The company has a 52-week low of $13.17 and a 52-week high of $43.98. On the Street’s front, the average 12-month analyst price target for the stock is $45.29, marking a 8.48% potential upside from current levels. In a report released today, Cowen analyst Ritu Baral maintained a Buy rating on ACAD, with a price target of $66, which implies an upside of 58% from current levels. Separately, on September 3, Stifel Nicolaus’ Paul Matteis maintained a Hold rating on the stock and has a price target of $28.

Exact Sciences is down -8.95% in midday trading to $110.39. Shares opened today at $121.25. The company has a 52-week low of $53.06 and a 52-week high of $123.99. On the Street’s front, the average 12-month analyst price target for the stock is $132.88, marking a 9.59% potential upside from current levels. In a report issued on September 3, Canaccord Genuity analyst Mark Massaro maintained a Buy rating on EXAS, with a price target of $135, which represents a potential upside of 11% from where the stock is currently trading.

Arrowhead Research is down -8.36% in midday trading to $28.82. Shares opened today at $31.45. The company has a 52-week low of $10.41 and a 52-week high of $36.80. On the Street’s front, the average 12-month analyst price target for the stock is $38.00, marking a 20.83% potential upside from current levels. In a report issued on August 19, B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on ARWR, with a price target of $46, which represents a potential upside of 46% from where the stock is currently trading. Separately, on June 27, Oppenheimer’s Justin Kim downgraded the stock to Hold . Over the last 3 months, the insider sentiment on Arrowhead Research has been negative based on 42 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Rite Aid Corp is up 7.35% in midday trading to $7.72. Shares opened today at $7.19. The company has a 52-week low of $5.04 and a 52-week high of $27.20.

See today’s analyst top recommended stocks >>

Veeva Systems is down -7.31% in midday trading to $146.76. Shares opened today at $158.34. The company has a 52-week low of $79.26 and a 52-week high of $176.90. On the Street’s front, the average 12-month analyst price target for the stock is $177.45, marking a 12.07% potential upside from current levels. In a report issued on August 28, J.P. Morgan analyst Sterling Auty maintained a Hold rating on VEEV, with a price target of $183, which represents a potential upside of 16% from where the stock is currently trading. Separately, on the same day, Needham’s Scott Berg maintained a Buy rating on the stock and has a price target of $187. In the last 30 days, insiders have sold $2.51M worth of VEEV shares. Over the last 3 months, the insider sentiment on Veeva Systems has been negative based on 128 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>